John Bencich
2015
In 2015, John Bencich earned a total compensation of $411.1K as Executive Vice President and Chief Financial Officer and Chief Operating Officer at OncoGenex Pharmaceuticals, a 31% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $53,820 |
|---|---|
| Option Awards | $26,491 |
| Salary | $307,500 |
| Stock Awards | $23,250 |
| Total | $411,061 |
Bencich received $307.5K in salary, accounting for 75% of the total pay in 2015.
Bencich also received $53.8K in non-equity incentive plan, $26.5K in option awards and $23.3K in stock awards.
Rankings
In 2015, John Bencich's compensation ranked 11,494th out of 13,638 executives tracked by ExecPay. In other words, Bencich earned more than 15.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,494 out of 13,638 | 16th |
Division Manufacturing | 4,406 out of 5,190 | 15th |
Major group Chemicals And Allied Products | 1,626 out of 1,854 | 12th |
Industry group Drugs | 1,344 out of 1,528 | 12th |
Industry In Vitro and In Vivo Diagnostic Substances | 63 out of 76 | 17th |
Source: SEC filing on September 21, 2017.
Bencich's colleagues
We found two more compensation records of executives who worked with John Bencich at OncoGenex Pharmaceuticals in 2015.
News
OncoGenex Pharmaceuticals CEO John Bencich's 2022 pay slips 7% to $1.5M
April 28, 2023
OncoGenex Pharmaceuticals CEO John Bencich's 2021 pay jumps 82% to $1.6M
April 21, 2022
OncoGenex Pharmaceuticals CEO Richard Stewart's 2020 pay jumps 30% to $1M
March 30, 2021
OncoGenex Pharmaceuticals CEO Richard Stewart's 2019 pay falls 27% to $797K
April 2, 2020
OncoGenex Pharmaceuticals CEO Richard Stewart's 2018 pay jumps 423% to $1.1M
March 28, 2019